Ready for the next draft: what will change in the regulation of AI medical devices by 2026
There’s a silent revolution underway in the way we regulate Artificial Intelligence in medicine. For years, the conversation has been all about validation: collecting data, measuring performance, defining protocols, proving that the model works.The logic was linear: if it works, it can be certified. But 2026 marks a turning point.It will no longer be enough…
How Risk-Based thinking drives digital trials
In recent years, clinical research has embraced a new vocabulary: decentralized, remote, hybrid, digitalized, connected. Terms that once belonged to the future now define our daily operations. With hybrid models (combining onsite visits with remote data collection) and the growing adoption of connected devices, ePRO platforms, study portals, and workflow management systems, clinical trials have…
The most common mistakes in digital trials (and how to avoid them)
There’s one thing no one admits openly, but anyone working in digital trials has learned the hard way: technology is brilliant when everything is under control, and ruthless the moment something slips. In digital environments (wearables, ePRO, platforms, real-time data), weak signals don’t exist. Every error grows. Every ambiguity multiplies. Every uncertainty becomes impossible to hide.…
Patients are evolving faster than trials: why clinical data are falling behind
In clinical research, we speak often about patient-centricity. Yet in the past two years something unexpected has happened: patients’ real lives have become more digital, more monitored, and more interconnected than the trials designed to study them. The patient has changed.Their data pathways have not. Not because the industry lacks intent, but because traditional study…
Post-Market 2.0: how continuous Real-World Evidence is redefining medical devices
There’s a silent but radical shift reshaping the value of medical devices, more than any new technology or algorithm. A shift born in real life: in patients’ routines, phones, homes, and clinical journeys. Its name is Real-World Evidence (RWE).And it is turning post-market from a formal requirement into a strategic engine of safety, performance, competitiveness,…
When compliance isn’t enough: when is a clinical study truly safe?
Many clinical studies begin with a reassuring sense of security: the protocol is approved, the documentation is complete, regulatory requirements are met. Yet anyone who actually works in clinical research knows this: initial compliance is not the same as safety. The real question is not whether a study is compliant today, it is what happens…
PMS and Real-World Data: when real evidence begins after the study
When a clinical study changes its nature For a long time, post-market was treated as a phase that comes after the study.A necessary surveillance activity, but separate from clinical research itself. Today, that approach no longer works. Medical devices, especially digital and connected ones, continue to generate data long after the last patient visit.And that…
Italian